<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the possibility of using a pharmacologic agent to modulate <z:mp ids='MP_0001799'>viral</z:mp> gene expression to target radiotherapy to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue </plain></SENT>
<SENT sid="1" pm="."><plain>In a mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, we had previously shown targeting of [(125)I]2'-fluoro-2'-deoxy-beta-D-5-iodouracil-arabinofuranoside ([(125)I]FIAU) to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> engineered to express the Epstein-Barr virus <z:chebi fb="0" ids="17748">thymidine</z:chebi> kinase (EBV-TK) </plain></SENT>
<SENT sid="2" pm="."><plain>Here we extend those results to targeting of a therapeutic radiopharmaceutical [(131)I]FIAU to slow or stop <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> or to achieve <z:mp ids='MP_0010537'>tumor regression</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>These outcomes were achieved in xenografts with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that constitutively expressed the EBV-TK </plain></SENT>
<SENT sid="4" pm="."><plain>With naturally infected EBV <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines (Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and gastric <z:mp ids='MP_0002038'>carcinoma</z:mp>), activation of <z:mp ids='MP_0001799'>viral</z:mp> gene expression by pretreatment with <z:chebi fb="0" ids="52717">bortezomib</z:chebi> was required </plain></SENT>
<SENT sid="5" pm="."><plain>Marked changes in <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> could also be achieved in naturally infected <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> herpesvirus <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> after pretreatment with <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi>-induced enzyme-targeted radiation therapy illustrates the possibility of pharmacologically modulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> gene expression to result in targeted radiotherapy </plain></SENT>
</text></document>